Transcriptional Changes in Isolated Human Adipocytes During Obesity

NCT ID: NCT06907212

Last Updated: 2025-04-02

Basic Information

• Recruitment Status: ENROLLING_BY_INVITATION
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-04-01
• Study Completion Date: 2025-09-01

Brief Summary

Adipocytes play an important role in our body through their function as metabolic energy stores in the form of fat deposits, which are stored when metabolic energy is in excess and released when energy levels are low. In severe obesity, adipose tissue grows through the production of more adipocytes from stem cells (hyperplasia) and the increase in the size of existing adipocytes (hypertrophy). This ability of adipocytes, to maintain their functionality during tissue expansion, is critical in determining the development of obesity-related comorbidities. However, not all adipocytes are the same as adipocyte function differs greatly depending on the depot in which they are found. To elucidate the mechanisms underlying adipocyte adaptability, it is necessary to obtain a deep systems biology understanding of how signaling in different types of adipocytes regulates metabolism and function. Currently, this research group is conducting a systems biology analysis of adipocyte plasticity in obesity in mouse models, but adipose tissue biopsies from different depots in humans are lacking and needed to investigate the regulation of adipocyte function and plasticity in humans. Such studies of adipocytes are crucial for the understanding how obesity affects adipose tissue function and leads to comorbidities.

Detailed Description

The development of overweight and obesity is associated with major changes in adipose tissue, including structural changes in cell type composition as well as gene expression in individual adipose tissue cell types. The molecular mechanisms underlying these changes are not yet known. The investigators therefore hypothesized that overweight and obesity cause changes in the transcriptional program of adipocytes and this leads to impaired function of adipocytes. This study will use advanced genomic technologies available that can measure the dynamic changes in the transcriptome and genomic landscape of isolated adipocytes from patient biopsies, to better understand which changes in the adipocytes in particular underlie the severe comorbidities that occur with the development of obesity. It is expected that the described project will contribute important knowledge about adipocyte-specific transcriptional programs that play a crucial role in obesity. This and thus may contribute to the knowledge required to develop adapted- and personalized medicines, or new therapeutic approaches to treat obesity and its associated diseases.

Recruitment of 100 subjects will be from patients referred for surgical cholecystectomies, herniotomies or similar operations at Bispebjerg Hospital. The control group will consist of study participants with a BMI ≥ 19 kg/m2 and < 25 kg/m2, and the "case" group will consist of study participants with a BMI ≥ 25 kg/m2. When including subjects, emphasis will be placed on achieving a control group of approximately 25 subjects and a "case" group of approximately 75 subjects with varying degrees of elevated BMI.

Conditions

Obesity, Abdominal; Adiposity

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Study Groups

Male and female participants with various BMI

Both male and female participants will be included, with the goal of creating a cohort in which all levels of BMI are equally present. Adipocytes of the abdominal subcutaneous and visceral adipose tissue depots will be isolated and sequenced to perform linear regression analysis of transcriptional networks across BMI.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Age > 18 years old
• BMI> 19 kg/m2
• Can receive oral and written information and give appropriate consent

Exclusion Criteria

• Active viral hepatitis, HIV positive
• Autoimmune diseases (i.e. lupus)
• Chronic use of corticosteroids (cortisone)
• Unable to give appropriate consent
• Contraindications for biopsy: bleeding tendency.
• Cancer or other comorbidity with an expected survival time of less than 12 months

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Bispebjerg Hospital

OTHER

Sponsor Role: collaborator

University of Southern Denmark

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Susanne Mandrup, PhD

Role: PRINCIPAL_INVESTIGATOR

s.mandrup@bmb.sdu.dk

Locations

Bispebjerg hospital

Copenhagen, , Denmark

Countries

Denmark

Related Links

https://www.sdu.dk/en/adiposign

Website of main investigating party

Other Identifiers

S-20200123

Identifier Type: -

Identifier Source: org_study_id